双支气管扩张剂治疗支气管扩张合并慢性阻塞性肺疾病的临床效果

Clinical effect of double bronchodilator in the treatment of patients with bronchiectasis complicated with chronic obstructive pulmonary disease

目的探讨双支气管扩张剂治疗支气管扩张合并慢性阻塞性肺疾病(COPD)的临床效果。方法选取2020年3月至4月收治的43例支气管扩张合并COPD患者作为研究对象,随机将其分为观察组(n=22)和对照组(n=21)。在常规治疗基础上,观察组给予格隆溴铵福莫特罗吸入气雾剂,对照组给予布地奈德福莫特罗吸入粉雾剂(Ⅰ)。比较两组的治疗效果。结果治疗后,观察组的第1秒用力呼气容积(FEV_(1))、第1秒用力呼气容积占用力肺活量的百分比(FEV_(1)/FVC)、呼气流量峰值(PEF)、动脉血氧分压(PaO_(2))显著高于对照组,动脉血二氧化碳分压(PaCO_(2))显著低于对照组(P<0.05);治疗后,两组的pH无显著差异(P>0.05)。两组的不良反应总发生率无显著差异(P>0.05)。治疗后,观察组的哮喘控制问卷(ACQ)及圣乔治呼吸问卷(SGRQ)评分均显著低于对照组(P<0.05)。结论双支气管扩张剂治疗支气管扩张合并COPD患者的临床效果显著。

Objective To investigate the clinical effect of double bronchodilator in the treatment of bronchiectasis complicated with chronic obstructive pulmonary disease(COPD).Methods A total of 43 patients with bronchiectasis complicated with COPD from March to April 2020 were selected as the study objeces and randomly divided into observation group(n=22)and control group(n=21).On the basis of routine treatment,the observation group was given glycopyrronium bromide and formoterol fumarate inbalation aerosol,and the control group was given budesonide and formoterol fumarate powder for inhalation(Ⅰ).The therapeutic effects of the two groups were compared.Results After treatment,the forced expiratory volume in one second(FEV_(1)),the percentage of forced expiratory volume in one second to forced vital capacity(FEV_(1)/FVC),peak expiratory flow(PEF)and arterial partial pressure of oxygen(PaO_(2))of the observation group were significantly higher than those of the control group,while arterial partial pressure of carbon dioxide(PaCO_(2))was significantly lower than that of the control group(P<0.05);after treatment,there was no statistically significant difference in pH between the two groups(P>0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).After treatment,the Asthma Control Questionnaire(ACQ)and St.George's Respiratory Questionnaire(SGRQ)scores in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Double bronchodilator in the treatment of patients with bronchiectasis complicated with COPD has a significant clinical effect.